Display options
Cite
Ibrahimagic OC, Smajlovic D, Dostovic Z, et al. HYPERHOMOCYSTEINEMIA AND ITS TREATMENT IN PATIENTS WITH PARKINSON'S DISEASE. Mater Sociomed. 2016;28(4):303-306doi: 10.5455/msm.2016.28.303-306.
Ibrahimagic, O. C., Smajlovic, D., Dostovic, Z., Pasic, Z., Kunic, S., Iljazovic, A., & Hajdarevic, D. S. (2016). HYPERHOMOCYSTEINEMIA AND ITS TREATMENT IN PATIENTS WITH PARKINSON'S DISEASE. Materia socio-medica, 28(4), 303-306. https://doi.org/10.5455/msm.2016.28.303-306
Ibrahimagic, Omer C, et al. "HYPERHOMOCYSTEINEMIA AND ITS TREATMENT IN PATIENTS WITH PARKINSON'S DISEASE." Materia socio-medica vol. 28,4 (2016): 303-306. doi: https://doi.org/10.5455/msm.2016.28.303-306
Ibrahimagic OC, Smajlovic D, Dostovic Z, Pasic Z, Kunic S, Iljazovic A, Hajdarevic DS. HYPERHOMOCYSTEINEMIA AND ITS TREATMENT IN PATIENTS WITH PARKINSON'S DISEASE. Mater Sociomed. 2016 Jul 24;28(4):303-306. doi: 10.5455/msm.2016.28.303-306. PMID: 27698607; PMCID: PMC5034996.
Copy Download .nbib Format: NLM
Share it on

Mater Sociomed. 2016 Jul 24;28(4):303-306. doi: 10.5455/msm.2016.28.303-306.

HYPERHOMOCYSTEINEMIA AND ITS TREATMENT IN PATIENTS WITH PARKINSON'S DISEASE.

Materia socio-medica

Omer C Ibrahimagic, Dzevdet Smajlovic, Zikrija Dostovic, Zejneba Pasic, Suljo Kunic, Amra Iljazovic, Denisa Salihovic Hajdarevic

Affiliations

  1. Department of Neurology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.

PMID: 27698607 PMCID: PMC5034996 DOI: 10.5455/msm.2016.28.303-306

Abstract

INTRODUCTION: Homocysteine is process-product of methionine demethylation. It has proatherogenic, prothrombotic, prooxidative, proapoptotic, osteoporotic, neurotoxic, neuroinflamatory, and neurodegenerative effects. Hyperhomocysteinemia correlates with C667T MTHFR mutation, decrease of folic acid and vitamin B, as well as prolonged use of certain medications.

MATERIALS AND METHODS: We measured levels of homocysteine in thirty patients (15::15) with "de novo" Parkinson's disease, with average age 64.17 ± 13.19 (28-82) years (Department of Neurology, University Clinical Center Tuzla). Normal level of homocysteine for women was 3.36-20.44 micromole/l and 5.9-16 micromole/l for men. We followed the effects of medicament approach (folic acid) every six months for next five years.

RESULTS: 20% of patients with "de novo" Parkinson's disease exhibited hyperhomocysteinemia. An average level of homocysteine was 13.85 ± 5.82 micromole/l. Differences due to age and homocysteine levels, regardless of sex, were not concluded. For the next five years intake of folic acid (periodically, 1-2 months, 5 mg per day, orally) was effective to normalized levels of homocysteine in all.

CONCLUSION: Hyperhomocysteinemia is present in every fifth patient with "de novo" Parkinson's disease. Folic acid is medication of choice in treatment of hyperhomocysteinemia coexisting with Parkinson's disease.

Keywords: Folic acid; Homocysteine; Parkinson’s disease

Conflict of interest statement

none

References

  1. Mov Disord. 2010 Feb 15;25(3):332-40 - PubMed
  2. Clin Chem. 2001 Jun;47(6):1102-4 - PubMed
  3. J Neurol Sci. 2006 Dec 1;250(1-2):58-61 - PubMed
  4. Tohoku J Exp Med. 2004 Oct;204(2):155-61 - PubMed
  5. Clin Chem Lab Med. 2003 Nov;41(11):1392-403 - PubMed
  6. Br J Nutr. 2010 Sep;104(5):757-64 - PubMed
  7. Parkinsonism Relat Disord. 2006 Mar;12(2):103-7 - PubMed
  8. Clin Neuropharmacol. 2006 Nov-Dec;29(6):305-11 - PubMed
  9. Am J Med. 2005 Nov;118(11):1250-5 - PubMed
  10. Neuropsychiatr Dis Treat. 2010 Sep 07;6:483-90 - PubMed
  11. Curr Med Chem. 2003 Oct;10(19):1923-9 - PubMed
  12. Neurol Res. 2006 Dec;28(8):853-8 - PubMed
  13. J Neurochem. 2002 Jan;80(1):101-10 - PubMed
  14. Trends Neurosci. 2003 Mar;26(3):137-46 - PubMed
  15. Recenti Prog Med. 2004 Jul-Aug;95(7-8):371-5; quiz 402 - PubMed
  16. Eur J Neurol. 2010 May;17(5):661-5 - PubMed
  17. Curr Vasc Pharmacol. 2006 Jul;4(3):237-43 - PubMed
  18. J Clin Neurosci. 2010 Jun;17(6):717-21 - PubMed
  19. Am J Pathol. 1969 Jul;56(1):111-28 - PubMed
  20. J Neural Transm (Vienna). 2001;108(10):1135-48 - PubMed
  21. Am J Hum Genet. 1998 Nov;63(5):1541-3 - PubMed
  22. Free Radic Biol Med. 2002 Jun 15;32(12):1264-75 - PubMed
  23. Neurol Sci. 2010 Oct;31(5):565-9 - PubMed

Publication Types